ASCO Advises Against PARP Inhibitor Retreatment in Ovarian Cancer
October 28, 2020 4:00 pmBy Andrew D. Bowser
However, trials investigating retreatment are underway, so this recommendation may change.
The guidelines, from … Read more
Tag: Olaparib
KSQ Boosts PARP Inhibition In Models Of Cancer With USP1 Inhibitor
October 27, 2020 7:00 pmKSQ Therapeutics is hoping to provide hope for ovarian and breast cancer patients that have developed a resistance to drugs and those who don’t respond at all by developing a drug that may be able to boost the effectiveness of … Read more
Triple therapy Shows Promise in Non-Germline BRCA-Mutated Ovarian Cancer
October 10, 2020 5:00 pmBy Savannah Demko
Triple therapy with olaparib plus durvalumab and bevacizumab were well-tolerated in patients with non-germline BRCA-mutated, platinum-sensitive, relapsed ovarian cancer, according to data presented at ESMO Virtual Congress 2020.
“Preclinical studies suggest the potential for synergy between … Read more
Halting Cancer by Halting DNA Repair
September 25, 2020 11:00 amBy Liam Drew
PARP inhibitors are rapidly transforming the treatment of ovarian, breast, prostate and other types of cancer. To develop these drugs, researchers supported by Cancer Research UK had to decipher how blocking DNA repair could expose a weak … Read more
Olaparib Improves Median Time Without Disease Progression in BRCAm Ovarian Cancer
September 18, 2020 3:00 pmOlaparib (Lynparza®; AstraZeneca/Merck & Co.*) has demonstrated a long-term progression-free survival (PFS) benefit versus placebo as a 1st-line maintenance treatment in patients with newly diagnosed, advanced BRCA-mutated (BRCAm) ovarian cancer who had a complete or partial response … Read more
ASCO Releases New Guidelines on PARP Inhibitor Use for Management of Ovarian Cancer
September 1, 2020 2:00 pmBy Hannah Slater
The recommendations were based on a review of 17 clinical trials, FDA approvals, and consensus where evidence was lacking.
The American Society for Clinical Oncology (ASCO) published new guidelines on the use of PARP inhibitors in the … Read more
New OS Data With Olaparib Support ‘New Era’ for Ovarian Cancer
May 14, 2020 10:00 amBy Liam Davenport
Women with platinum-sensitive relapsed ovarian cancer and a BRCA mutation could see their survival extended by over a year by maintenance therapy with the PARP-inihibitor olaparib (Lynparza, AstraZeneca).
The new overall survival (OS) data come … Read more
FDA Approves Lynparza/Avastin With Myriad Genetics CDx for Platinum-Sensitive Ovarian Cancer
May 11, 2020 10:00 amNEW YORK – The US Food and Drug Administration has approved olaparib (AstraZeneca/Merck’s Lynparza) in combination with bevacizumab (Genentech’s Avastin) as a maintenance regimen for advanced ovarian cancer patients who have homologous recombination deficiency (HRD) and are responding to first-line … Read more
FDA Approves Combination of Lynparza and Avastin as Maintenance Treatment for Advanced Ovarian Cancer
May 8, 2020 10:00 amBy Beth Fand Incollingo
The Food and Drug Administration (FDA) has approved the combination of two targeted drugs, Lynparza (olaparib) and Avastin (bevacizumab), for patients with advanced ovarian cancer who have responded to initial treatment with platinum-based chemotherapy plus Avastin … Read more
Olaparib Matches Chemotherapy Outcomes in Platinum-Sensitive Recurrent Ovarian Cancer
April 17, 2020 10:30 amBy Lisa Astor
Treatment with olaparib demonstrated similar outcomes to standard-of-care chemotherapy treatment in patients with BRCA wild-type, platinum-sensitive, recurrent epithelial ovarian cancer in the phase II CLIO study. As such, olaparib failed to demonstrate a significant improvement in survival … Read more
Olaparib/Bevacizumab as Frontline Maintenance Improves PFS in Ovarian Cancer, Regardless of Timing of Surgery, Disease Status
April 8, 2020 10:00 amBy Gina Columbus
The combination of olaparib (Lynparza) and bevacizumab (Avastin) was found to improve progression-free survival (PFS) outcomes versus bevacizumab alone as a frontline maintenance treatment in patients with newly diagnosed advanced high-grade serous ovarian cancer, regardless of the … Read more
Olaparib Plus Durvalumab Show Durable Activity in Germline BRCA+ Breast, Ovarian Cancer
October 11, 2019 5:00 pmBy Wayne Kuznar
The case for the combination of olaparib (Lynparza) and durvalumab (Imfinzi) in patients with metastatic breast cancer and relapsed ovarian cancer with germline BRCA mutations was strengthened based on the updated results from the phase I/II MEDIOLA, … Read more
First-Line Combo Boosts PFS in Advanced Ovarian Cancer
September 28, 2019 5:00 pmBy Charles Bankhead
Olaparib-bevacizumab maintenance boosts PARP inhibitor benefits beyond BRCA-mutated subgroup.
Dual maintenance therapy with olaparib (Lynparza) and bevacizumab (Avastin) significantly improved progression-free survival (PFS) in women with newly diagnosed advanced ovarian cancer, as compared with single-agent bevacizumab, a … Read more
AstraZeneca’s Ovarian Cancer Drug Hits Main Goal in New Study
August 13, 2019 5:15 amBy John Lauerman
AstraZeneca Plc’s Lynparza got a boost from results of a study that may widen the drug’s use among patients with advanced ovarian cancer.
Ovarian tumor growth slowed in patients who got Lynparza in addition to a … Read more
Trial Examines Tolerance of Maintenance Olaparib in Advanced Ovarian Cancer
June 12, 2019 5:00 pmBy Dave Levitan
An analysis of the phase III SOLO1 trial found no new safety signals when the PARP inhibitor olaparib was given as maintenance therapy for women with newly diagnosed advanced ovarian cancer and a BRCA mutation. Nausea, fatigue, … Read more
SOLO3 Examines Benefit of Olaparib vs Chemo in Platinum-Sensitive Relapsed Ovarian Cancer
June 5, 2019 8:00 pmPatients with BRCA-mutated, platinum-sensitive relapsed ovarian cancer derived significant clinical benefit from treatment with olaparib monotherapy compared with treatment of physician’s choice, according to the results of the SOLO3 trial, a US Food and Drug Administration … Read more
Study Identifies How Cancer Drug Inhibits DNA Repair in Cancer Cells
May 15, 2019 6:00 pmAccording to researchers at Yale Cancer Center, a cancer drug thought to be of limited use possesses a superpower of sorts: It is able to stop certain cancer cells from repairing their DNA in order to survive. The study, published … Read more
FDA Approves Lynparza for Maintenance Treatment of BRCA-Mutant Gynecologic Cancers
December 19, 2018 5:00 pmBy Brielle Benyon
The Food and Drug Administration (FDA) approved Lynparza (olaparib) for the maintenance treatment of adults with deleterious or suspected deleterious germline or somatic BRCA-mutated advanced epithelial ovarian, fallopian tube or primary peritoneal cancer who are in a
… Read more
Ovarian Cancer ‘Breakthrough’ Drug Prevents Disease Returning for Years
October 22, 2018 4:35 pmBy
A new ovarian cancer treatment dramatically reduces the chances of the disease returning, a study has shown.
Doctors have hailed the results of a “breakthrough” trial which they say opens the possibility that many more women suffering … Read more
Olaparib Plus Vistusertib Promising in Early Trial
June 8, 2018 9:48 pmThe combination of the PARP inhibitor olaparib with an mTORC1/2 inhibitor known as vistusertib was tolerable and had promising activity across endometrial, ovarian, and triple-negative breast cancers, according to a phase I trial. Results of the trial (abstract 5504… Read more